CORE1: Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

被引：0

作者：

Rixe, Olivier ^{[1
]}

Castonguay, Vincent ^{[2
]}

Conter, Henry ^{[3
]}

Chalas, Eva ^{[4
]}

Desai, Pratibha

Squillante, Christian ^{[5
]}

MacDonald, Lisa A. ^{[6
]}

Conlon, Rebekah ^{[6
]}

Bramhecha, Yogesh ^{[6
]}

Hirsch, Heather ^{[6
]}

Graff, Jeremy R. ^{[6
]}

Fiset, Stephan ^{[7
]}

机构：

[1] Quantum Santa Fe, Santa Fe, NM USA

[2] Univ Laval, CRCHU Quebec, Quebec City, PQ, Canada

[3] William Osler Hlth Syst, Brampton, ON, Canada

[4] NYU Langone Hosp, Perlmutter Canc Ctr, Mineola, NY USA

[5] Allina Hlth, Minneapolis, MN USA

[6] IMV Inc, Dartmouth, NS, Canada

[7] IMV Inc, Quebec City, PQ, Canada

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT036

引用

页数：2

共 50 条

[21] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
de Wit, R.
Kamat, A. M.
Bellmunt, J.
Choueiri, T. K.
Nam, K.
De Santis, M.
Dreicer, R.
Hahn, N. M.
Perini, R.
Siefker-Radtke, A. O.
Sonpavde, G.
Witjes, J. A.
Keefe, S.
Bajorin, D.
ANNALS OF ONCOLOGY, 2016, 27
[22] Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).
Sfakianos, John
Shore, Neal D.
Zhuang, John
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Bacillus Calmette-Guerin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
Tan, Wei Shen
Grajales, Valentina
Bree, Kelly
Li, Roger
Nogueras-Gonzalez, Graciela M.
Navai, Neema
Dinney, Colin
Kamat, Ashish M.
BJU INTERNATIONAL, 2023, 132 (04) : 384 - 386
[24] Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer
Sylvester, Richard J.
INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (02) : 113 - 120
[25] Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guerin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer
Joshi, Mrinmayee
Atlas, Steven J.
Beinfeld, Molly
Chapman, Richard H.
Rind, David M.
Pearson, Steven D.
Touchette, Daniel R.
VALUE IN HEALTH, 2023, 26 (06) : 823 - 832
[26] Outcomes of Intravesical Bacillus Calmette-Guerin (BCG) in patients with Non-Muscle Invasive Bladder Cancer: A retrospective study in Australia
Pillippuhewa, Chamodi
Della-Fiorentina, Stephen
Haghighi, Kayvan
Chau, Wei
Kok, Peey-Sei
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 61 - 61
[27] Bacillus Calmette-Guerin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
Steinberg, Ryan L.
Thomas, Lewis J.
O'Donnell, Michael A.
BLADDER CANCER, 2015, 1 (02) : 105 - 116
[28] INTERIM RESULTS FROM A SINGLE-ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Packiam, Vignesh T.
Barocas, Daniel A.
Chamie, Karim
Davis, Ronald L., III
Kader, A. Karim
Lamm, Donald L.
Curran, Dominic
Yeung, Alex W.
Steinberg, Gary D.
JOURNAL OF UROLOGY, 2017, 197 (04): : E915 - E916
[29] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
Kamat, Ashish M.
Bellmunt, Joaquim
Choueiri, Toni K.
Nam, Kijoeng
De Santis, Maria
Dreicer, Robert
Hahn, Noah M.
Perini, Rodolfo F.
Siefker-Radtke, Arlene O.
Sonpavde, Guru
De Wit, Ronald
Witjes, Alfred
Keefe, Stephen Michael
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
Steinberg, Ryan L.
Thomas, Lewis J.
Mott, Sarah L.
O'Donnell, Michael A.
BLADDER CANCER, 2016, 2 (02) : 215 - 224

← 1 2 3 4 5 →